Back to Journals » Cancer Management and Research » Volume 7 » default
Cancer Management and Research
ISSN: 1179-1322
- View all (4649)
- Volume 16, 2024 (55)
- Volume 15, 2023 (153)
- Volume 14, 2022 (330)
- Volume 13, 2021 (890)
- Volume 12, 2020 (1256)
- Volume 11, 2019 (969)
- Volume 10, 2018 (645)
- Volume 9, 2017 (89)
- Volume 8, 2016 (17)
- Volume 7, 2015 (33)
- Volume 6, 2014 (43)
- Volume 5, 2013 (41)
- Volume 4, 2012 (47)
- Volume 3, 2011 (32)
- Volume 2, 2010 (32)
- Volume 1, 2009 (17)
Archive: Volume 7, 2015
Development and validation of an immunohistochemistry assay to assess glucocorticoid receptor expression for clinical trials of mifepristone in breast cancer
Baker GM, Murphy T, Block T, Nguyen D, Lynch FJ
Cancer Management and Research 2015, 7:361-368
Published Date: 4 December 2015
Durable response using regorafenib in an elderly patient with metastatic colorectal cancer: case report
Tang R, Kain T, Herman J, Seery T
Cancer Management and Research 2015, 7:357-360
Published Date: 19 November 2015
Clinical utility of RapidArcTM radiotherapy technology
Infusino E
Cancer Management and Research 2015, 7:345-356
Published Date: 12 November 2015
Rationale and development of image-guided intensity-modulated radiotherapy post-prostatectomy: the present standard of care?
Murray JR, McNair HA, Dearnaley DP
Cancer Management and Research 2015, 7:331-344
Published Date: 11 November 2015
Critical appraisal of rituximab in the maintenance treatment of advanced follicular lymphoma
Aguiar-Bujanda D, Blanco-Sánchez MJ, Hernández-Sosa M, Galván-Ruíz S, Hernández-Sarmiento S
Cancer Management and Research 2015, 7:319-330
Published Date: 27 October 2015
Prospective noninterventional study on the use of panitumumab monotherapy in patients with recurrent or progressive colorectal cancer: the VECTIS study
Lakomy R, Rogowski W, Piko B, Mihaylova Zh, Pritzova E, Kvocekova L
Cancer Management and Research 2015, 7:311-318
Published Date: 23 October 2015
Atypical teratoid rhabdoid tumors: a population-based clinical outcomes study involving 174 patients from the Surveillance, Epidemiology, and End Results database (1973–2010)
Lau CS, Mahendraraj K, Chamberlain RS
Cancer Management and Research 2015, 7:301-309
Published Date: 18 September 2015
Targeting autophagy in cancer management – strategies and developments
Ozpolat B, Benbrook DM
Cancer Management and Research 2015, 7:291-299
Published Date: 11 September 2015
Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia in Ukraine
Mandrik O, Corro Ramos I, Knies S, Al M, Severens JL
Cancer Management and Research 2015, 7:279-289
Published Date: 25 August 2015
The treatment landscape in thyroid cancer: a focus on cabozantinib
Weitzman SP, Cabanillas ME
Cancer Management and Research 2015, 7:265-278
Published Date: 19 August 2015
Progress toward overcoming hypoxia-induced resistance to solid tumor therapy
Karakashev SV, Reginato MJ
Cancer Management and Research 2015, 7:253-264
Published Date: 12 August 2015
Potential of epigenetic therapies in the management of solid tumors
Valdespino V, Valdespino PM
Cancer Management and Research 2015, 7:241-251
Published Date: 31 July 2015
New and emerging factors in tumorigenesis: an overview
Kim S
Cancer Management and Research 2015, 7:225-239
Published Date: 28 July 2015
Clinical management of grade III oligodendroglioma
Simonetti G, Gaviani P, Botturi A, Innocenti A, Lamperti E, Silvani A
Cancer Management and Research 2015, 7:213-223
Published Date: 27 July 2015
Review of advanced catheter technologies in radiation oncology brachytherapy procedures
Zhou J, Zamdborg L, Sebastian E
Cancer Management and Research 2015, 7:199-211
Published Date: 16 July 2015
Treatment of metastatic colorectal cancer: focus on panitumumab
Tay RY, Wong R, Hawkes EA
Cancer Management and Research 2015, 7:189-198
Published Date: 24 June 2015
The impact of 5-hydroxytryptamine-receptor antagonists on chemotherapy treatment adherence, treatment delay, and nausea and vomiting
Palli SR, Grabner M, Quimbo RA, Rugo HS
Cancer Management and Research 2015, 7:175-188
Published Date: 16 June 2015
5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus sunitinib or bevacizumab as first-line treatment for metastatic colorectal cancer: a randomized Phase IIb study
Hecht JR, Mitchell EP, Yoshino T, Welslau M, Lin X, Chow Maneval E, Paolini J, Lechuga MJ, Kretzschmar A
Cancer Management and Research 2015, 7:165-173
Published Date: 15 June 2015
A profile of enzalutamide for the treatment of advanced castration resistant prostate cancer
Greasley R, Khabazhaitajer M, Rosario DJ
Cancer Management and Research 2015, 7:153-164
Published Date: 12 June 2015
New developments in the treatment of peripheral T-cell lymphoma – role of Belinostat
Reimer P
Cancer Management and Research 2015, 7:145-151
Published Date: 3 June 2015
Cancer therapy and cardiovascular risk: focus on bevacizumab
Economopoulou P, Kotsakis A, Kapiris I, Kentepozidis N
Cancer Management and Research 2015, 7:133-143
Published Date: 3 June 2015
The impact of mindfulness-based interventions on symptom burden, positive psychological outcomes, and biomarkers in cancer patients
Rouleau CR, Garland SN, Carlson LE
Cancer Management and Research 2015, 7:121-131
Published Date: 1 June 2015
Expanding role of lenalidomide in hematologic malignancies
Ghosh N, Grunwald MR, Fasan O, Bhutani M
Cancer Management and Research 2015, 7:105-119
Published Date: 2 May 2015
Long-term survival in advanced melanoma patients using repeated therapies: successive immunomodulation improving the odds?
Coventry BJ, Baume D, Lilly C
Cancer Management and Research 2015, 7:93-103
Published Date: 29 April 2015
Pharmacokinetics, safety, and efficacy of APF530 (extended-release granisetron) in patients receiving moderately or highly emetogenic chemotherapy: results of two Phase II trials
Gabrail N, Yanagihara R, Spaczyński M, Cooper W, O’Boyle E, Smith C, Boccia R
Cancer Management and Research 2015, 7:83-92
Published Date: 17 March 2015
Afatinib for the treatment of metastatic non-small cell lung cancer
Joshi M, Rizvi SM, Belani CP
Cancer Management and Research 2015, 7:75-82
Published Date: 19 February 2015
Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma
Gunnarsson O, Pfanzelter NR, Cohen RB, Keefe SM
Cancer Management and Research 2015, 7:65-73
Published Date: 11 February 2015
New and emerging therapeutic options for malignant pleural mesothelioma: review of early clinical trials
Kotova S, Wong RM, Cameron RB
Cancer Management and Research 2015, 7:51-63
Published Date: 23 January 2015
Ipilimumab was safe and effective in two patients with metastatic melanoma and end-stage renal disease
Cavalcante L, Amin A, Lutzky J
Cancer Management and Research 2015, 7:47-50
Published Date: 19 January 2015
Management of patients with hormone receptor–positive breast cancer with visceral disease: challenges and treatment options
Harb WA
Cancer Management and Research 2015, 7:37-46
Published Date: 19 January 2015
Lung and colorectal cancer treatment and outcomes in the Veterans Affairs health care system
Zullig LL, Williams CD, Fortune-Britt AG
Cancer Management and Research 2015, 7:19-35
Published Date: 14 January 2015
Utilization of bone densitometry for prediction and administration of bisphosphonates to prevent osteoporosis in patients with prostate cancer without bone metastases receiving antiandrogen therapy
Holt A, Khan MA, Gujja S, Govindarajan R
Cancer Management and Research 2015, 7:13-18
Published Date: 24 December 2014
Minimizing second cancer risk following radiotherapy: current perspectives
Ng J, Shuryak I
Cancer Management and Research 2015, 7:1-11
Published Date: 17 December 2014